Castle Biosciences, Inc. Common Stock (CSTL) — Analysis Summary
Castle Biosciences, Inc. Common Stock (CSTL) has a market cap of $1.00B with year-over-year revenue growth of +3.7%. Net margin stands at -7.0%. The stock trades at a P/E ratio of -51.5.
Key Takeaways
- Revenue changed +3.7% year-over-year
- Net margin of -7.0%
- P/E ratio of -51.5
Compared to other companies in the SERVICES-MEDICAL LABORATORIES sector, CSTL posted revenue growth of +3.7% and trades at a P/E of -51.5.
Castle Biosciences, Inc. Common Stock (CSTL)
PREVIOUS CLOSE 2026-10-12 · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -81.1x — earnings do not cover interest payments
Free cash flow turned negative after being positive in the prior period.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
Sector
SERVICES-MEDICAL LABORATORIES
Employees
1,002
Headquarters
FRIENDSWOOD, TX
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.